Oxidative stress and high-density lipoprotein function in Type I diabetes and end-stage renal disease

Clinical Science

Volumn 108, Issue 6, 2005, Pages 497-506

  Kalogerakis, George ^a   Baker, Arthur M ^a   Christov, Steve ^a   Rowley, Kevin G ^a   Dwyer, Karen ^a   Winterbourn, Christine ^b   Best, James D ^a   Jenkins, Alicia J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

End stage renal disease; High density lipoprotein; Lipid peroxide; Oxidative stress; Paraoxonase 1; Protein carbonyl; Type I diabetes

Indexed keywords

ARYLDIALKYLPHOSPHATASE; CARBONYL DERIVATIVE; HIGH DENSITY LIPOPROTEIN; LIPID PEROXIDE;

ARTICLE; BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC ANGIOPATHY; ENZYME ACTIVITY; FEMALE; GLYCATION; HIGH RISK POPULATION; HUMAN; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; LIPID OXIDATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DETERMINATION;

ADULT; ANALYSIS OF VARIANCE; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; ERYTHROCYTE MEMBRANE; FEMALE; HUMANS; KETONES; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; RENAL DIALYSIS;

EID: 20444433542     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20040312     Document Type: Article

References (56)

1. Pyorala, K., Laasko, M. and Vusitupra, M. (1987) Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab. Rev. 3, 464-524
2. American Diabetes Association (2001) Diabetes 2001 Vital Statistics, pp. 75-85, American Diabetes Association, Alexandria, VA
3. Wheeler, D. C. (1996) Cardiovascular disease in patients with chronic renal failure. Lancet 348, 1673-1674
4. Hasselwander, O., McEneny, J., McMaster, D. et al. (1999) HDL composition and HDL antioxidant capacity in patients on regular hemodialysis. Atherosclerosis 143, 125-133
5. Lyons, T. J. and Jenkins, A. J. (1997) Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis. Diabetes Rev. 5, 365-391
6. Miyata, T., van Ypersele de Strihou, C., Kurokawa, K. and Baynes, J. W. (1999) Alterations in nonenzymatic biochemistry in uremia: origin and significance of 'carbonyl stress' in long-term uremic complications. Kidney Int. 55, 389-399
7. Kitiyakara, C., Ginin, J., Massy, Z. and Wilcox, C. S. (2000) Non-traditional cardiovascular disease risk factors in end-stage renal disease: oxidative stress and hyperhomocysteinemia. Curr. Opin. Nephrol. Hypertens. 9, 477-487
8. Sangvanich, P., Mackness, B., Gaskell, S. J., Durrington, P. and Mackness, M. (2003) The effect of high-density lipoproteins on the formation of lipid/protein conjugates during in vitro oxidation of low-density lipoprotein. Biochem. Biophys. Res. Commun. 300, 501-506
9. Rousselot, D. B., Therond, P., Beaudeux, J. L., Peynet, J., Le-Grand, A. and Delattre, J. (1999) High density lipoproteins (HDL) and the oxidative hypothesis of atherosclerosis. Clin. Chem. Lab. Med. 37, 939-948
10. Navab, M., Hama, S. Y., Cooke, C. J. et al. (1998) Normal high density lipoprotein inhibits three steps in the formation of mildly oxidised low density lipoprotein: step 1. J. Lipid Res. 39, 1133-1140
11. Deakin, S. P. and James, R. W. (2004) Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin. Sci. 107, 435-447
12. Laplaud, P. M., Dantoine, T. and Chapman, M. J. (1998) Paraoxonase as a risk marker for cardiovascular disease: facts and hypotheses. Clin. Chem. Lab. Med. 36, 431-441
13. Berliner, J. A. and Heinecke, J. W. (1996) The role of oxidized lipoproteins in atherogenesis. Free Radical Biol. Med. 20, 707-727
14. Buss, I. H. and Winterbourn, C. C. (2002) Protein carbonyl measurement by ELISA. Methods Mol. Biol. 186, 123-128
15. Winterbourn, C. C. and Buss, I. H. (1999) Protein carbonyl measurement by enzyme-linked immunosorbent assay. Methods Enzymol. 300, 106-111
16. Dodge, J. T. and Phillips, G. B. (1966) Autoxidation as a cause of altered lipid distribution in extracts from human red cells. J. Lipid Res. 7, 387-395
17. Lowry, O. H., Rosenbrough, N. J., Farr, A. L. and Randall, R. J. (1951) Protein measurement with the Folin reagent. J. Biol. Chem. 193, 265-275
18. Cohen, J., Jenkins, A. J., Karschimkus, C. et al. (2002) Paraoxonase and other coronary risk factors in a community-based cohort. Redox Rep. 7, 1-4
19. Jenkins, A. J., Klein, R. L., Zheng, D. et al. (2000) Paraoxonase genotype (192 Gln-Arg) and serum paraoxonase-arylesterase activity: relationship with type 1 diabetes and nephropathy, American Diabetes Association 60th Scientific Session, Abstract 643-P
20. Nourooz-Zadeh, J., Tajaddini-Sarmadi, J. and Wolff, S. P. (1994) Measurements of plasma hydroperoxide concentrations by the ferrous oxidation-xylenol orange assay in conjunction with triphenylphosphine. Anal. Biochem. 220, 403-409
21. 2+ in the presence of xylenol orange. Free Radical Res. 31, 237-244
22. Reference deleted
23. Makita, Z., Radoff, S., Rayfield, E. J. et al. (1991) Advanced glycosylation end products in patients with diabetic nephropathy. N. Engl. J. Med. 325, 836-842
24. Lee, C. T., Rowley, K., Jenkins, A. J. et al. (2004) Paraoxonase activity in Greek migrants and Anglo-Celtic persons in the Melbourne Collaborative Cohort Study: relationship to dietary markers, Eur. J. Nutr., DOI 10.1007/s00394-004-0514-y
25. Vincent-Viry, M., Sass, C., Bastien, S., Aguillon, D., Siest, G. and Visvikis, S. (2003) PON1-192 phenotype and genotype assessments in 918 subjects of the Stanislas cohort study. Clin. Chem. Lab. Med. 41, 535-540
26. Mackness, B., Durrington, P. N., Boulton, A. J., Hine, D. and Mackness, M. I. (2002) Serum paraoxonase activity in patients with type I diabetes compared to healthy controls. Eur. J. Clin. Invest. 32, 223-224
27. Jenkins, A. J., Best, J. D., Klein, R. L. and Lyons, T. J. (2004) Lipoproteins, glycoxidation and diabetic angiopathy. Diabetes Metab. Res. Rev. 20, 349-368
28. Dantoine, T. F., Debord, J., Charmes, J. P. et al. (1998) Decrease in paraoxonase activity in chronic renal failure. J. Am. Soc. Nephrol. 9, 2082-2088
29. Mackness, M. I., Durrington, P. N. and Mackness, B. (2000) How high-density lipoprotein protects against the effects of lipid peroxidation. Curr. Opin. Lipidol. 11, 383-388
30. Mackness, M. I. and Durrington, P. N. (1995) HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 115, 243-253
31. Lyons, T. J. and Jenkins, A. J. (1997) Glycation, oxidation and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis. Diabetes Rev. 5, 365-391
32. Martin-Gallan, P., Carrascosa, A., Gussinye, M. and Dominguez, C. (2003) Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radical Biol. Med. 34, 1563-1574
33. Odetti, P., Garibaldi, S., Noberasco, G. et al. (1999) Levels of carbonyl groups in plasma proteins of type 2 diabetes mellitus subjects. Acta Diabetol. 36, 179-183
34. Ghiselli, A., Laurenti, O., De Mattia, G., Maiani, G. and Ferro-Luzzi, A. (1992) Salicylate hydroxylation as an early marker of in vivo oxidative stress in diabetic patients. Free Radical Biol. Med. 13, 621-626
35. Altomare, E., Vendemiale, G., Chicco, D., Procacci, V. and Cirelli, F. (1992) Increased lipid peroxidation in type 2 poorly controlled diabetic patients. Diabetes Metab. 18, 264-271
36. Pryor, W. A. and Godberg, S. S. (1991) Noninvasive measures of oxidative stress status in humans. Free Radical Biol. Med. 10, 177-184
37. Ceriello, A., Giugliano, D., Quattaro, A., Del Russo, P. and Lefebvre, P. J. (1991) Metabolic control may influence the increased superoxide generation in human serum. Diabetic Med. 8, 540-542
38. Jenkins, A. J., Klein, R. L., Chassereau, C. N., Hermayer, K. L. and Lopes-Virella, M. F. (1996) LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation. Diabetes. 45, 762-767
39. Tsai, E. C., Hirsch, I. B., Brunzell, J. D. and Chait, A. (1994) Reduced plasma peroxyl trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 43, 1010-1014
40. Stamler, J. (1987) Epidemiology, established major risk factors and the primary prevention of coronary heart disease. In Cardiology (Palmley, W. and Chatterjee, K., eds.), pp. 1-41, Lippincott, Philadelphia
41. The DCCT research group (1993) The effect of intensive diabetes treatment on the development and progression of lone-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications trial. N. Engl. J. Med. 329, 977-986
42. Lyons, T. J. and Kennedy, A. L. (1997) Glycation, oxidation and lipoxidation in the development of diabetic complications. Metabolism. 46 (Suppl. 1), 14-21
43. Mackness, M. I., Harty, D., Bhatnagar, D. et al. (1991) Serum paraoxonase activity in familial hypercholesterolemia and insulin dependent diabetes mellitus. Atherosclerosis 86, 193-199
44. Banka, C. L. (1996) High density lipoprotein and lipoprotein oxidation. Curr. Opin. Lipidol. 7, 139-142
45. Aviram, M. A., Billecke, S., Sorenson, R. et al. (1998) Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/ paraoxonase activities. Arterioscler., Thromb., Vasc. Biol. 18, 1617-1624
46. Boemi, M., Leviev, I., Sirolla, C., Fieri, C., Marra, M. and James, R. W. (2001) Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 155, 229-235
47. Hasselwander, O., McMaster, D., Fogarty, D. G., Maxwell, A. P., Nicholls, D. P. and Young, I. S. (1998) Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure. Clin. Chem. 44, 179-181
48. Graham, A., Hassall, D. G., Rafique, S. and Owen, J. S. (1997) Evidence for a paraoxonase-independent inhibition of low density lipoprotein oxidation by high density lipoprotein. Atherosclerosis 135, 193-204
49. Stafforini, D. M., Zimmerman, G. A., McIntyre, T. M. and Prescott, S. M. (1993) The platelet-activating factor acetylhydrolase from human plasma prevents oxidative modification of low density lipoprotein. Trans. Assoc. Am. Physicians 10, 44-63
50. Watson, A. D., Navab, M., Hama, S. Y. et al. (1995) Effect of platelet-activating factor acetylhydrolase on the formation and action of minimally oxidized low-density lipoprotein. J. Clin. Invest. 95, 774-782
51. Rodrigo, L., Mackness, B., Durrington, P. N., Hernandez, A. and Mackness, M. I. (2001) Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem. J. 354, 1-7
52. Duell, P. B., Oram, J. F. and Bierman, E. L. (1991) Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes 40, 377-384
53. Ceriello, A., Quatraro, A. and Giugliano, D. (1992) New insights on non-enzymatic glycosylation may lead to therapeutic approaches for the prevention of diabetic complications. Diabetic Med. 9, 297-299
54. Hedrick, C. C., Thorpe, S. R., Fu, M.-X. et al. (2000) Glycation impairs high-density lipoprotein function. Diabetologia 3, 312-320
55. Ferretti, G., Bacchetti, T., Busni, D., Rabini, A. and Curatola, G. (2004) Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. J. Clin. Endocrinol. Metab. 89, 2957-2962
56. Circio, F. and Ceriello, A. (1992) Decreased cultured endothelial cell proliferation in high glucose medium is reversed by antioxidants: new insights on the pathophysiological mechanisms of diabetic vascular complications. In Vitro Cell. Dev. Biol. 28A, 787-790